Beyond Human Leukocyte Antigen Class I Antigens: Hereditary Hemochromatosis Gene Mutations in Recurrent Aphthous Oral Ulcers and Behçet Disease in the South of Tunisia

Sahar ElAoud, Arwa Kamoun, Nadia Mahfoudh, Aida Charfi, Mouna Snoussi, Hend Hachicha, Ameni Jerbi, Chifa Dammak, Feten Frika, Faiza Hakim, Lilia Gaddour, Zouheir Bahloul, Hafedh Makni

Departments of Internal Medicine and Histocompatibility, Hedi Chaker Hospital, and Immunology Department, Habib Bourguiba Hospital, Sfax, Tunisia

Abstract

Objective: The aim of this work was to establish human leukocyte antigen (HLA) class I and hereditary hemochromatosis gene (HFE) mutation associations with recurrent aphthous oral ulcers (RAOU) and Behçet disease (BD) in a cohort of Southern Tunisian patients. Subjects and Methods: A total of 232 patients with RAOU and 123 healthy controls (HCs) were enrolled in this study. The patients were divided into 2 groups based on the presence (BD+: n = 62) or absence of BD (BD−, n = 170). In the BD+ group, 28 patients had severe manifestations of BD. In the BD− group, RAOU was isolated in 81 patients, associated with mucocutaneous manifestations in 58 and with joint symptoms in 25. Complement-dependent microlymphocytotoxicity assay and polymerase chain reaction-restriction fragment length polymorphism were used to study HLA class I polymorphism and HFE mutations, respectively. Results: HLA-B51 was positively associated with BD, particularly in those with severe manifestations. No association was detected with HLA class I polymorphism among the BD group. Based on stratification to clinical manifestations, the isolated RAOU was negatively associated with HLA-A1 with a difference close to significance (12 [14.81%] vs. 32 [26.02%] in HCs; p = 0.06). Furthermore, patients with mucocutaneous features had a higher frequency of HLA-B51 (14, 24.14%) than patients without mucocutaneous involvement (11, 11.37%). Considering HFE mutations, patients with isolated RAOU had a higher frequency of H63D when compared with other subgroups, especially after limiting the comparison to 27 patients of at least 5 years of follow-up. Conclusion: This study showed that, unlike BD, RAOU were not associated with HLA-B51. Moreover, we suggest that H63D mutation was positively associated with isolated RAOU.

Keywords
Behçet disease · Recurrent aphthous oral ulcers · Human leukocyte antigen class I polymorphism · Hereditary hemochromatosis gene mutations

Significance of the Study
In this study, HLA-B51 carriage increased the risk of skin involvement in Behçet disease and in recurrent aphthous oral ulcers (RAOU). Hence, HFE could be a potential susceptibility gene for isolated RAOU.
Introduction

Recurrent aphthous oral ulcers (RAOU) are characterized by recurrent inflammatory painful ulcers that recur at intervals of a few days or months. The condition is reported to affect 20% of the general population at any time [1]. Three clinical presentations of RAOU have been recognized: minor recurrent aphthous stomatitis, major recurrent aphthous stomatitis, and herpetiform ulceration. These lesions can be isolated alone or in combination with other conditions, or as part of a multiorgan syndrome, especially Behçet disease (BD) [2].

BD is a multisystem inflammatory disorder. It is characterized by skin, ocular, joint, central nervous system, vascular, and intestinal manifestations of varying severity [2]. ROAU is often the initial feature in most patients with BD and is a major criterion according to the International Study Group for Behçet’s Disease criteria for the diagnosis of this disease [3]. It is generally present with at least 2 of the following: recurrent genital ulceration, eye lesions, skin lesions, or a positive pathergy test [2]. It is difficult to predict those patients initially presenting with ROAU who will subsequently proceed to develop other features of BD.

Histocompatibility human leukocyte antigen (HLA) typing is not a diagnostic criterion for BD. Nevertheless, studies on HLA associations with BD considered HLA-B51 antigen as the strongest evidence of a BD genetic background. Indeed, some reports also implicated the probable role of HLA antigen inheritance in the RAOU immunopathogenesis [4–5].

The hereditary hemochromatosis gene (HFE) is a major histocompatibility class I-like molecule. It is located on the short arm of chromosome 6, approximately 4 Mb telomeric to the HLA-A locus [6]. Linkage disequilibrium was demonstrated between the HFE mutations and HLA-A and HLA-B alleles in particular [7]. The HFE mutation is encountered in hereditary hemochromatosis [6]. It is also implicated in other diseases, such as neoplasia [8–10] and myelodysplastic syndromes [11]. Its association with RAOU or BD has not yet been described. Therefore, the aim of this study was to investigate whether or not HLA class I and HFE mutations are associated with RAOU and BD in a group of Southern Tunisian patients.

Materials and Methods

Study Population

The study included 232 patients with RAOU who were seen from January 2007 to December 2013 at the Department of Internal Medicine, Hedi Cheker University Hospital, Sfax, Tunisia. The patients included in this study were selected from subjects enrolled in an ongoing case-control study designed to investigate the frequency of the different alleles HLA-A and HLA-B in these patients, and to study different HFE mutations in linkage disequilibrium with these HLA antigens.

The clinical features of the patients are shown in Table 1. The patients with RAOU were divided into 2 groups based on the presence (BD+) or absence (BD−) of BD. The diagnosis of BD was made according to the criteria of the International Study Group for Behçet’s Disease.

The BD+ group included 62 patients (41 men and 21 women). Severe cases were defined as those with at least 1 ocular, gastrointestinal, vascular, or neurological involvement (28 patients).

The BD− group included 170 patients (76 men and 94 women). RAOU was isolated in 81 patients and associated with other clinical features in 89 patients in whom the criteria for BD were not fulfilled (Table 1). The associated manifestations were distributed as follows: mucocutaneous manifestations were found in 58 patients and joint symptoms in 25 patients. Mucocutaneous features included genital ulcers, a positive pathergy test, and erythema nodosum. Five patients had uveitis and 1 patient experienced venous thrombosis. These 6 latter patients were excluded from HLA class I and HFE subgroup analysis.

For healthy controls (HCs), 123 unrelated healthy Tunisian subjects with no history of RAOU were recruited. All patients and controls gave written informed consent for their participation in the study.

Laboratory Methods

The HLA-class I (A and B) typing was performed on freshly peripheral blood mononuclear cells separated on a Ficoll gradient from 20 mL of citrate-phosphate-dextrose-collected venous blood, by the standard complement-dependent microlymophocytotoxicity assay. For HFE mutations analysis, DNA was extracted from 5 mL of heparinized blood by the salting out technique. The DNA was available for our 123 HCs and 208 patients. The identification of H63D, C282Y, and S65C mutations was carried out by polymerase chain reaction-restriction fragment length polymorphism [12].

Statistical Analysis

Data analysis was performed using the Statistical Package for Social Sciences (version 20.0; SPSS, Chicago, IL, USA). A value of \( p < 0.05 \) was regarded as statistically significant. Odds ratios (OR) and 95% confidence intervals (CI) were calculated according to the Woolf method.

Results

HLA Class I

For the BD+ groups, the association of HLA class I antigens with BD based on clinical manifestations and in comparison with HCs is summarized in Table 2. Regarding the epidemiological findings, women had a higher frequency of HLA-B14 than male patients (4 [19.05%] vs. 1 [2.44%]; \( p = 0.023 \)). For the clinical aspects, the frequen-
cy of HLA-B51 positivity was significantly higher in BD+ patients compared to the control group (17 [27.42%] vs. 12 [9.76%]; *p* = 0.002). However, the HLA-B35 was less frequent in BD+ patients when compared to the HCs (4 [6.45%] vs. 21 [17.07%]; **p** = 0.046). Among 34 patients without severe manifestations, 9 (26.47%) had joint involvement. HLA-B51 was expressed in none of them.

Regarding the BD− group, the association of HLA class I antigens with RAOU based on clinical manifestations and in comparison with HCs is summarized in Table 3, and no association was detected between HLA class I polymorphism and RAOU. The male patients had a higher frequency of HLA-A68 (9 [11.8%] vs. 3 [3.1%]; *p* = 0.03) and of HLA-B45 (9 [11.8%] vs. 1 [1%]; *p* = 0.003) than female patients. Based on stratification to clinical manifestations, HLA-A1 was less frequent in the patients with isolated RAOU than HCs (12 [14.81%] vs. 32 [26.02%]; *p* = 0.06). HLA-B51 was positively associated with mucocutaneous features (14 [24.14%] vs. 12 [9.76%] in HCs; *p* = 0.01).

**Table 1.** Patient repartition according to clinical features

| Group | Subgroup | Number |
|-------|----------|--------|
| BD− (n = 170; 76 male and 94 female) | Isolated RAOU | 81 |
| | RAOU with mucocutaneous manifestations | 58 |
| | RAOU with joint involvement, without mucocutaneous manifestations | 25 |
| BD+ (n = 62; 41 male and 21 female) | No severe BD | 34 |
| | Severe BD with uveitis, neurological, or vascular involvement | 28 |

BD, Behçet disease; RAOU, recurrent aphthous oral ulcers; SG, subgroup.

**Table 2.** HLA class I association with BD according to clinical manifestations and in comparison with HCs

| HLA antigen | BD+ (n = 62) | SGA (n = 34) | SGB (n = 28) | HCs (n = 123) |
|-------------|-------------|-------------|-------------|-------------|
| A1          | 15 (24.19)  | 6 (17.6)    | 9 (32)      | 32 (26.02)  |
| A23         | 6 (9.68)    | 4 (11.8)    | 2 (7.1)     | 10 (8.13)   |
| A24         | 4 (6.45)    | 1 (2.9)     | 3 (10.7)    | 20 (16.26)  |
| B8          | 5 (8.06)    | 3 (8.8)     | 2 (7)       | 16 (13)     |
| B27         | 3 (4.84)    | 2 (5.9)     | 1 (3.6)     | 3 (2.44)    |
| B35         | 4 (6.45)**  | 2 (5.9)     | 2 (7.1)     | 21 (17.07)  |
| B51         | 17 (27.42)**| 8 (23.5)    | 9 (32)**    | 12 (9.76)   |

Data are presented as *n* (%). BD, Behçet disease; SG, subgroup; HCs, healthy controls. Compared with HCs: *p* = 0.046 (OR 0.33, 95% CI 0.11–1.01); **p** = 0.002 (OR 2.03, 95% CI 1.54–7.89); ***p** = 0.005 (OR 4.38, 95% CI 1.62–11.81).

Compared with patients with mucocutaneous or joint involvement (SG2 and SG3), the isolated RAOU subgroup (SG1) had a lower frequency of HLA-A1 with a difference close to significance (12 [14.1%] vs. 23 [25.8%]; *p* = 0.07). The patients with mucocutaneous involvement had a higher frequency of HLA-B51 (14 [24.14%]) vs. 12 [10.7%]; *p* = 0.02). When comparing the 2 groups, the HLA-B51 frequency was significantly lower in the BD− group (26, 15.29%) than in the BD+ group (17, 27.42%; *p* = 0.03). The HLA-B51 association with BD+ and BD− patients is illustrated in Figure 1 based on the clinical manifestations and in comparison with HCs.

**HFE Mutations**

The S65C mutation was not detected in the population studied. However, RFLP analysis revealed C282Y in 3 HCs and in none of the patients. The H63D distribution is given in Table 4. Compared with the HCs, the analysis did not reveal any significant difference in the distribution of the HFE mutation in the BD− and BD+ groups. Compared with other patients with mucocutaneous or joint involvement, patients with isolated RAOU had a higher frequency of H63D mutation (29 [39.2%] vs. 20 [24.4%]; *p* = 0.04). This association strengthened and became more significant when comparisons were limited to patients of at least 5 years of follow-up (20 [50%] vs. 7 [17.1%]; *p* = 0.002).

**Discussion**

In this report, HLA-B51 was positively associated with BD patients when compared with HCs, which is consistent with the results of a previous study [13]. It has also been reported that HLA-B51 is considered as a risk factor in BD among Asian populations [14], Caucasians [15, 16], and Mediterranean people [17, 18].

**Figure 1.** HLA-B51 association with BD− and BD+ patients in relation to clinical manifestations.
The finding that HLA-B35 was protective in these patients confirmed a report from Spain [19]. However, it contrasts with the findings of Shahneh et al. [20], who reported that HLA-B35 conferred susceptibility to BD in Iranians.

The finding of HLA class I disease phenotypic correlations revealed a significant positive association of HLA-B51 with severe manifestations, including uveitis and vascular involvement. This confirmed the finding of Hamzaoui et al. [21] in which the HLA-B51 antigen was significantly associated with a positive pathergy test and retinal vasculitis.

HLA-B51 is the strongest susceptibility factor described so far affecting the disease risk. Nevertheless, a meta-analysis [22] provided evidence that HLA-B51 positivity had only a modest BD phenotype-modifying effect. Moreover, the strong association of HLA-B51 with BD could reflect linkage disequilibrium with another putative susceptibility gene. In fact, analyses of multicase families showed a substantial contribution of non-HLA loci on chromosome 6 at position D6S285, 13 Mb telomeric to HLA-B [23].

RAOU is usually the initial feature of BD. It is a major criterion according to the International Study Group for Behçet’s Disease criteria for the diagnosis of this disease [3]. It can be isolated for many years before developing other clinical features as part of BD. In this study, there was no association between the HLA class I polymor-

---

Table 3. HLA class I association with BD− patients according to clinical manifestations and in comparison with HCs

| HLA antigen | BD− (n = 170) | SG1 (n = 81) | SG2 (n = 58) | SG3 (n = 25) | HCs (n = 123) |
|-------------|--------------|-------------|-------------|-------------|--------------|
| A1          | 35 (20.59)   | 12 (14.81)* | 16 (27.6)   | 6 (24)      | 32 (26.02)   |
| A23         | 26 (15.29)   | 11 (13.58)  | 8 (13.8)    | 6 (24)      | 10 (8.13)    |
| A24         | 17 (10)      | 10 (12.35)  | 3 (5.17)**  | 3 (12)      | 20 (16.26)   |
| B8          | 16 (9.41)    | 5 (6.2)     | 8 (13.8)    | 1 (4)       | 16 (13)      |
| B27         | 6 (3.53)     | 3 (3.7)     | 3 (5.17)    | 0           | 3 (2.44)     |
| B35         | 21 (12.35)   | 10 (12.35)  | 6 (10.34)   | 4 (16)      | 21 (17.07)   |
| B51         | 26 (15.29)   | 10 (12.35)  | 14 (24.14)** | 1 (4)       | 12 (9.76)    |

Data are presented as n (%). BD, Behçet disease; SG, subgroup; HCs, healthy controls. * p = 0.06 when compared with HCs (OR 0.49, 95% CI 0.24–1.02), p = 0.07 when compared with other subgroups of BD− patients; ** p = 0.04 when compared with HCs (OR 0.28, 95% CI 0.08–0.98); *** p = 0.01 when compared with HCs (OR 2.94, 95% CI 1.26–6.85), p = 0.02 when compared with other subgroups of BD− patients.

---

Fig. 1. HLA-B51 association with BD+ and BD− patients according to clinical manifestations and in comparison with HCs. BDJF, BD with joint features; RAOUJF, RAOU with joint features; RAOUMCF, RAOU with mucocutaneous features; BDMCF, BD with mucocutaneous features; HCs, healthy controls.
Phytism and RAOU, but HLA-B51 association with mucocutaneous features could support the hypothesis that the presence of skin lesions in patients with RAOU could be a risk factor for the development of BD [2].

The results of other studies of HLA in RAOU patients remain inconsistent. In Turkish populations [24], there was no association between RAOU and HLA-B51. Pekiner et al. [25] found that the HLA-A24 frequency was significantly higher in the RAOU patient group than in healthy subjects. In Brazilians, RAOU was associated with HLA-A33, HLA-B35, and HLA-B81 [26]. In Caucasians, patients with RAOU showed a higher frequency of HLA-B12 [27], HLA-DR7, and HLA-DR5 [28], and lower incidence of HLA-B5 and HLA-DR4 [28] when compared with HCs. The discrepancies could be due to the ethnic background of the condition, but also might be a consequence of unequal patient qualification criteria. Nevertheless, a noteworthy similarity in all these studies, including ours, is the lack of association of HLA-B51 with RAOU.

We suggested that a susceptibility locus for RAOU could reside in the telomeric segment to HLA-B. The finding of a lack of association of H63D, the most common HFE mutation, with BD confirmed the previous findings of Gul et al. [23]. On the other hand, the present study revealed the association of H63D with isolated RAOU.

Mutations in the HFE gene result in iron overload and disturb its intestinal absorption with consequent hereditary hemochromatosis [6]. The increased incidence of malignancy in patients with common HFE mutations remains controversial. They were implicated in breast [8], gastrointestinal [9], and liver [10] cancers. In fact, iron is a potential carcinogen [29]. It induces oxidative stress by catalyzing hydroxyl radical formation. Hussain et al. [30] found that 28% of hemochromatosis cases showed a higher expression of inducible nitric oxide synthase (NOS) in the liver, which suggests NO as a source of increased oxidative stress. Some reports also suggest the role of endothelial NOS gene polymorphisms in the development of RAOU [5]. In fact, the development of a sustained oxidative and nitrosative stress, and the subsequent generation of lipid peroxidation, protein modification, and DNA damage can promote RAOU. Such results are in concordance with the high frequency of H63D mutation in our patients with isolated RAOU, which has not been previously reported.

**Conclusion**

BD was mainly associated with HLA-B51 in Southern Tunisia. This antigen was not associated with RAOU; however, it had an impact on clinical features associated with RAOU. Finally, this study is the first to confirm the association of H63D with isolated RAS.

**Disclosure Statement**

The authors have no conflicts of interest to declare.

| Table 4. H63D mutation distribution in patients and HCs |
|-----------------------------------------------|
| H63D genotype | BD– group (n = 156) | BD+ group (n = 52) | HCs (n = 123) |
|----------------|-------------------|-------------------|---------------|
| BD– (n = 156)  | SG1 (n = 74) | SG2 (n = 51) | SG3 (n = 25) | BD+ (n = 52) | SGA (n = 31) | SGB (n = 21) | HCs |
| HD or DD       | 49 (31.4)         | 12 (23.5)         | 6 (24)        | 11 (21.2)    | 7 (22.6)   | 4 (19.0)   | 35 (28.5) |
| HH             | 107 (68.6)        | 39 (76.5)         | 19 (76)       | 41 (78.8)    | 24 (77.4)  | 17 (80.9)  | 88 (71.5) |

Data are presented as n (%). BD, Behçet disease; SG, subgroup; HCs, healthy controls; HD, H63D heterozygote; DD, H63D homozygote; HH, H63H homozygote. *p = 0.04 when compared with other subgroups of BD– patients.

**References**

1. Field EA, Allan RB: Oral ulceration – aetio-pathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment Pharmacol Ther 2003;18:949–962.
2. Nair JR, Moots RJ: Behçet’s disease. Clin Med 2017;17:71–77.
3. International Study Group for Behçet’s Disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–1080.
4. Wilhelmns NS, Weber R, Montiero F, et al: Correlation between histocompatibility antigens and recurrent aphthous stomatitis in the Brazilian population. Braz J Otorhinolaryngol 2009;75:426–431.
